Hormonal
Incretin-based therapies (GLP-1 and dual GIP/GLP-1 receptor agonists) administered for 12 months in adults with obesity and type 2 diabetes significantly reduce body weight, improve glycemic control, and provide multi-organ protection (cardiovascular, renal, and hepatic).
If you have obesity and type 2 diabetes, incretin-based medications (like semaglutide or tirzepatide) are highly effective for losing weight (average 10.7%), lowering blood sugar, and protecting your heart, kidneys, and liver. These benefits are consistent across different healthcare settings in Latin America. Discuss these options with your doctor, especially if you are concerned about injection frequency, as oral alternatives are emerging.
After 12 months of treatment, participants exhibited consistent and clinically significant improvements in all outcome domains. Mean body weight decreased by 10.7%, HbA1c by 1.3 percentage points, and fasting glucose by 23.5%, accompanied by favorable reductions in blood pressure and lipid levels.
Why this rating
The study is a multinational, multicenter observational/analytical study with a large sample size (n=1,230), but it is not a randomized controlled trial (RCT).
Source
Revolución metabólica: redefiniendo la endocrinología con nuevas terapias basadas en incretinas
Alexis Ramírez Hernández et al. · Star of Sciences Multidisciplinary Journal · 2025
DOI 10.63969/tg610p62
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →